sur ONCODESIGN PRECISION MEDICINE S.A. (isin : FR001400CM63)
OPM presents its 2026 half-year financial results
Oncodesign Precision Medicine (OPM) has released its financial results for the first half of 2026. Funding has been secured from the Michael J. Fox Foundation for the development of OPM-201 for Parkinson's disease. In addition, the company is making progress in the clinical trial of OPM-101 for advanced melanoma.
Despite a 21% reduction in revenue, operating expenses have been significantly reduced since 2024. This has led to a 32% improvement in operating result, reaching -€2.2 million, excluding the exceptional effect of inventory in 2025.
With €2.86 million in cash reserves as of June 30, 2026, including an initial payment from the foundation, OPM is continuing its discussions to secure new partners and funding. However, its continued operation remains contingent upon obtaining additional funds.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ONCODESIGN PRECISION MEDICINE S.A.